TMCnet News

Research and Markets: Varicella Zoster (HHV-3) Infections Therapeutic Development Pipeline Review, H2 2014 - 7 Companies and 10 Drug Profiles
[August 21, 2014]

Research and Markets: Varicella Zoster (HHV-3) Infections Therapeutic Development Pipeline Review, H2 2014 - 7 Companies and 10 Drug Profiles


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/qmbg54/varicella_zoster) has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

strong>Scope



  • The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Companies Involved in Therapeutics Development

  • Novavax, Inc.
  • SK Chemicals Co., Ltd.
  • Green Cross Corporation
  • Beijing Tiantan Biological Products Co., Ltd.
  • Epiphany Biosciences, Inc.
  • China National Pharmaceutical Group Corporation
  • Chongqing Zhifei Biological Products Co., Ltd.

Drug Profiles


  • valomaciclovir stearate
  • Vaccine for Varicella Zoster Infections
  • measles + mumps + rubella + varicella vaccine
  • MG-1111
  • measles + mumps + rubella + varicella vaccine
  • Varicella Vaccine
  • Varicella Zoster Virus Vaccine
  • Small Molecules to Inhibit Cyclophilins
  • Sattabacin
  • HHV-3 vaccine

For more information visit http://www.researchandmarkets.com/research/qmbg54/varicella_zoster


[ Back To TMCnet.com's Homepage ]